Your browser is no longer supported. Please, upgrade your browser.
Amryt Pharma plc
Index- P/E- EPS (ttm)-2.39 Insider Own- Shs Outstand35.88M Perf Week-5.43%
Market Cap725.21M Forward P/E101.27 EPS next Y0.11 Insider Trans- Shs Float21.15M Perf Month-8.99%
Income-80.80M PEG- EPS next Q-0.17 Inst Own24.70% Short Float1.51% Perf Quarter1.46%
Sales203.00M P/S3.57 EPS this Y-24.70% Inst Trans0.12% Short Ratio2.90 Perf Half Y-17.85%
Book/sh1.37 P/B8.13 EPS next Y125.00% ROA-15.40% Target Price- Perf Year-8.84%
Cash/sh2.20 P/C5.07 EPS next 5Y- ROE-132.20% 52W Range9.55 - 15.44 Perf YTD-21.33%
Dividend- P/FCF15.05 EPS past 5Y31.50% ROI-16.10% 52W High-27.85% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin47.50% 52W Low16.65% ATR0.40
Employees99 Current Ratio2.20 Sales Q/Q35.90% Oper. Margin-8.30% RSI (14)38.28 Volatility4.08% 3.30%
OptionableYes Debt/Eq4.03 EPS Q/Q67.80% Profit Margin-39.80% Rel Volume2.25 Prev Close11.21
ShortableYes LT Debt/Eq4.02 Earnings- Payout- Avg Volume109.86K Price11.14
Recom1.70 SMA20-6.25% SMA50-3.46% SMA200-10.61% Volume247,020 Change-0.62%
Aug-19-21Initiated SVB Leerink Outperform $22
Aug-19-21Initiated Cowen Outperform $22
Jul-27-21Initiated H.C. Wainwright Buy $29
Oct-20-21 07:00AM  
Oct-19-21 07:00AM  
Oct-14-21 06:57AM  
Oct-01-21 02:00AM  
Sep-27-21 11:55AM  
Sep-13-21 07:00AM  
Sep-01-21 02:00AM  
Aug-19-21 02:00AM  
Aug-10-21 09:20AM  
Aug-09-21 07:00AM  
Aug-06-21 07:00AM  
Aug-05-21 10:50AM  
Jul-28-21 10:00AM  
Jul-12-21 07:00AM  
Jun-28-21 07:00AM  
Jun-15-21 06:45AM  
Jun-10-21 09:32AM  
Jun-07-21 07:00AM  
Jun-04-21 09:35AM  
Jun-03-21 08:07AM  
Jun-02-21 08:30AM  
May-06-21 03:54PM  
May-05-21 05:36PM  
Apr-17-21 09:20AM  
Apr-15-21 07:00AM  
Apr-06-21 02:00AM  
Mar-31-21 02:00AM  
Mar-30-21 02:00AM  
Mar-29-21 02:00AM  
Mar-23-21 03:00AM  
Mar-22-21 03:00AM  
Mar-15-21 06:00AM  
Mar-12-21 02:00AM  
Mar-11-21 06:30AM  
Mar-08-21 01:00PM  
Feb-24-21 02:00AM  
Feb-04-21 02:00AM  
Jan-20-21 02:00AM  
Dec-23-20 02:00AM  
Dec-17-20 02:00AM  
Dec-11-20 05:00AM  
Dec-09-20 09:45AM  
Dec-08-20 02:00AM  
Nov-29-20 08:33PM  
Nov-05-20 07:00AM  
Oct-29-20 03:00AM  
Oct-19-20 02:00AM  
Oct-12-20 06:00AM  
Oct-09-20 02:00AM  
Oct-08-20 02:00AM  
Oct-01-20 02:00AM  
Sep-30-20 07:30AM  
Sep-23-20 07:00AM  
Sep-21-20 06:00AM  
Sep-15-20 07:00AM  
Sep-09-20 07:01AM  
Aug-11-20 06:09AM  
Aug-06-20 07:01AM  
Aug-03-20 04:42PM  
Jul-29-20 07:00AM  
Jul-20-20 07:00AM  
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.